Theravance Biopharma, Inc. Announces Results From Phase 2 Study of Nezulcitinib In Patients Hospitalized With Acute Lung Injury Due to COVID-19; Co. Reports 'Randomized, double-blind, placebo-controlled study did not meet the primary endpoint'